Bioverativ has reported results from their ongoing Phase III trial of Alprolix in children under 12. Thirty patients under 12 (median, 5 years of age) received once-weekly infusions of Alprolix. Overall, 80% of patients were able to reduce their infusion frequency from that on their previous product. The mean half-life was 68.6 hours. Ten patients reported no bleeding and 19 patients exhibited no joint bleeding. Four patients experienced severe adverse events, but no inhibitor development was observed.